Lessee, Operating Lease, Liability, to be Paid, Year One of Lexaria Bioscience Corp. from 31 Aug 2020 to 30 Nov 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
- Summary
-
Lexaria Bioscience Corp. quarterly Lessee, Operating Lease, Liability, to be Paid, Year One in USD history and change rate from 31 Aug 2020 to 30 Nov 2025.
- Lexaria Bioscience Corp. Lessee, Operating Lease, Liability, to be Paid, Year One for the quarter ending 30 Nov 2025 was $28,009.
- Source SEC data
- View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year One, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year One, YoY Quarterly Change (%)
Lexaria Bioscience Corp. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year One (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $28,009 | +$28,009 | 30 Nov 2025 | 10-Q | 13 Jan 2026 | 2026 | Q1 | |
| Q3 2025 | $38,642 | +$38,642 | 31 Aug 2025 | 10-K | 28 Nov 2025 | 2025 | FY | |
| Q2 2025 | $37,345 | +$28,386 | +317% | 31 May 2025 | 10-Q | 14 Jul 2025 | 2025 | Q3 |
| Q1 2025 | $37,345 | +$19,427 | +108% | 28 Feb 2025 | 10-Q | 14 Apr 2025 | 2025 | Q2 |
| Q4 2024 | $0 | -$26,878 | -100% | 30 Nov 2024 | 10-Q | 10 Jan 2025 | 2025 | Q1 |
| Q3 2024 | $0 | -$35,840 | -100% | 31 Aug 2024 | 10-K | 26 Nov 2024 | 2024 | FY |
| Q2 2024 | $8,959 | 31 May 2024 | 10-Q | 12 Jul 2024 | 2024 | Q3 | ||
| Q1 2024 | $17,918 | -$17,922 | -50% | 29 Feb 2024 | 10-Q | 09 Apr 2024 | 2024 | Q2 |
| Q4 2023 | $26,878 | -$6,733 | -20% | 30 Nov 2023 | 10-Q | 12 Jan 2024 | 2023 | Q1 |
| Q3 2023 | $35,840 | 31 Aug 2023 | 10-K | 20 Nov 2023 | 2023 | FY | ||
| Q1 2023 | $35,840 | 31 Mar 2023 | 10-Q | 14 Jul 2023 | 2023 | Q3 | ||
| Q4 2022 | $33,611 | 30 Nov 2022 | 10-Q/A | 18 Jan 2023 | 2023 | Q1 | ||
| Q2 2022 | $44,815 | +$33,828 | +308% | 31 May 2022 | 10-K | 28 Nov 2022 | 2022 | FY |
| Q2 2021 | $10,987 | 31 May 2021 | 10-Q | 15 Jul 2021 | 2021 | Q3 | ||
| Q1 2021 | $21,975 | 28 Feb 2021 | 10-Q | 14 Apr 2021 | 2021 | Q2 | ||
| Q4 2020 | $32,746 | 30 Nov 2020 | 10-Q | 14 Jan 2021 | 2021 | Q1 | ||
| Q3 2020 | $43,950 | 31 Aug 2020 | 10-K | 15 Oct 2020 | 2020 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.